Verastem, INC Form 4 insider transactions

Verastem's President and CEO, Dan Paterson, reported sales of common stock totaling 3,299 shares on November 3, 2025, including shares for tax withholding and a 10b5-1 plan.

Verastem Director Paul A. Bunn sold 8,333 shares of common stock for a weighted average price of $9.06 per share pursuant to a Rule 10b5-1 trading plan.

Verastem's Chief Financial Officer, Daniel Calkins, sold a total of 82 shares of common stock to cover tax withholding requirements related to restricted stock unit vesting.

Verastem Director Brian M Stuglik sold 587 shares of common stock to satisfy statutory withholding requirements related to restricted stock unit vesting.

Verastem Director Robert E. Gagnon sold 281 shares of common stock to cover tax withholding requirements related to RSU vesting.

Verastem's President and CEO, Dan Paterson, sold 390 shares of common stock to cover tax withholding requirements related to restricted stock unit vesting.

Verastem, Inc.'s President and CEO, Dan Paterson, sold 1,332 shares of common stock to cover tax withholding requirements related to restricted stock unit vesting.

Verastem, Inc. President and CEO, Dan Paterson, sold 17,808 shares of common stock at $5.13 per share on June 20, 2025, to satisfy tax withholding requirements related to restricted stock unit vesting.

Verastem, Inc.'s Chief Financial Officer, Daniel Calkins, reported the sale of company common stock totaling 4,135 shares in June 2025, primarily to satisfy tax withholding requirements related to restricted stock unit vesting.

Verastem, Inc.'s President and CEO, Dan Paterson, reported the sale of 335 shares of common stock on June 16, 2025, at $5.65 per share, solely to satisfy statutory tax withholding requirements related to the vesting of restricted stock units.

Verastem, Inc. Director Robert E. Gagnon sold 284 shares of common stock on June 16, 2025, to satisfy tax withholding requirements related to restricted stock unit vesting.

Verastem, Inc. Director Brian M. Stuglik sold 594 shares of common stock at $5.65 per share to satisfy statutory withholding requirements related to restricted stock unit vesting.

Verastem, Inc. Director Michelle Robertson was granted 8,333 Restricted Stock Units (RSUs) and options to purchase 12,500 shares of common stock, aligning her compensation with long-term company performance.

Verastem, Inc. Director Paul A. Bunn was granted 8,333 Restricted Stock Units and options to purchase 12,500 shares of common stock, with vesting tied to continued service.

Verastem, Inc. Director Anil Kapur was granted 8,333 Restricted Stock Units (RSUs) and options to purchase 12,500 shares of common stock, vesting over approximately one year, as reported in a recent SEC Form 4 filing.

Verastem, Inc. Director Brian M. Stuglik reported the acquisition of 8,333 restricted stock units and 12,500 stock options as part of his compensation, aligning his interests with the company's long-term performance.

Verastem, Inc. Director Robert E. Gagnon was granted 8,333 Restricted Stock Units and 12,500 stock options, aligning his compensation with the company's long-term performance.

Verastem, Inc. Director Michael Kauffman was granted 8,333 Restricted Stock Units (RSUs) and 12,500 stock options, aligning his interests with shareholders through performance-based vesting.

Verastem, Inc. Director Karin Anna Tollefson was granted 8,333 Restricted Stock Units and 12,500 stock options on May 22, 2025, as part of her compensation under the company's equity incentive plan.

Verastem, Inc. Director John Johnson was granted 8,333 Restricted Stock Units and 12,500 stock options, aligning his compensation with the company's performance and shareholder interests.

Verastem, Inc. Director Eric K. Rowinsky was granted 8,333 Restricted Stock Units and options to purchase 12,500 shares of common stock, vesting over approximately one year.

Daniel Calkins, CFO of Verastem, Inc., reports acquisition and disposal of company stock following the FDA approval of the company's combination therapy.

Verastem's CEO, Dan Paterson, reports acquisition and disposal of company stock following the FDA approval of the avutometinib and defactinib combination therapy.

Verastem's CEO, Dan Paterson, sold 820 shares of common stock on May 5, 2025, to cover statutory withholding requirements related to the vesting of restricted stock units.

Verastem's Chief Operating Officer, Matthew Ros, acquired 50,000 shares of common stock on April 1, 2025, through a grant of restricted stock units.

Daniel Calkins, CFO of Verastem, Inc., sold shares of common stock to cover statutory withholding requirements related to the vesting of restricted stock units.

Verastem's CEO, Dan Paterson, sold 244 shares of common stock on March 17, 2025, to cover statutory withholding requirements related to the vesting of restricted stock units.

Director Robert E. Gagnon sold 284 shares of Verastem, Inc. common stock on March 17, 2025, to satisfy tax withholding requirements related to vesting restricted stock units.

Director Brian M. Stuglik sold 593 shares of Verastem, Inc. common stock on March 17, 2025, to cover statutory withholding requirements related to vesting restricted stock units.

Verastem's CEO, Dan Paterson, sold 858 shares of common stock on February 4, 2025, to cover statutory withholding requirements related to vesting restricted stock units.